The FDA has approved lutetium Lu-177 dotatate injection (Bexlutry), a new option for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Bexlutry is a radioligand
CDH17 Remains a Promising Target, Even as the CHM CDH17 Trial Changes Course The CHM CDH17 clinical trial, a CAR T-cell therapy built on research
The Neuroendocrine Tumor Research Foundation (NETRF) is deeply grateful to Citizens of Humanity for donating $28,000 through the sale of The Lindz, a jean created
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Same organ, different disease Words matter in cancer, especially when the name of an organ becomes
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Why do some neuroendocrine tumors grow slowly for years, while others progress more quickly? Researchers have
We recently spoke with John Metzcar, PhD, president of AMEND USA, neuroendocrine cancer patient and bioinformatics researcher. Can you share a little bit about yourself
By Anna Greene, PhD, Chief Scientific Officer, Neuroendocrine Tumor Research Foundation At NETRF, we often talk about the importance of funding foundational science. These studies
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Clinical trial news in neuroendocrine cancer is moving quickly. In this roundup, we highlight recent developments
By Anna C. Greene, PhD, NETRF Chief Scientific Officer When someone is diagnosed with metastatic neuroendocrine cancer, one of the most confusing questions can be:
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Patients often hear similar-sounding terms: neuroendocrine tumor, neuroendocrine carcinoma, NET, NEC, high-grade, poorly differentiated, well-differentiated. It